{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:07:49Z","timestamp":1772107669873,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This retrospective cohort study aimed to investigate the association between gout and Parkinson\u2019s disease (PD) in Korea. Materials and Methods: Overall, 327,160 patients with gout and 327,160 age- and sex-matched controls were selected from the Korean National Health Insurance Service (NHIS) database. PD incidence was evaluated by reviewing NHIS records during the period from 2002 to 2019. Patients with a diagnosis of gout (International Classification of Diseases-10 (ICD-10), M10) who were prescribed medications for gout, including colchicine, allopurinol, febuxostat, and benzbromarone for at least 90 days were selected. Patients with PD who were assigned a diagnosis code (ICD-G20) and were registered in the rare incurable diseases (RID) system were extracted. Results: During follow-up, 912 patients with gout and 929 control participants developed PD. The incidence rate (IR) of overall PD (per 1000 person-years) was not significantly different between both groups (0.35 vs. 0.36 in gout and control groups, respectively). The incidence rate ratio (IRR) was 0.98 (95% CI: 0.89\u20131.07). The cumulative incidence of PD was not significantly different between the groups. No association between gout and PD was identified in univariate analysis (HR = 1.00, 95% CI: 0.91\u20131.10, p = 0.935). HR increased significantly with old age (HR = 92.08, 198, and 235.2 for 60\u201369 years, 70\u201379 years, and over 80 years, respectively), female sex (HR = 1.21, 95% CI: 1.07\u20131.37, p = 0.002), stroke (HR = 1.95, 95% CI: 1.76\u20132.16, p &lt; 0.001), and hypertension (HR = 1.16, 95% CI: 1.01\u20131.34, p = 0.04). Dyslipidemia exhibited an inverse result for PD (HR = 0.6, 95% CI: 0.52\u20130.68, p &lt; 0.001). Conclusions: This population-based study did not identify an association between gout and PD. Age, female sex, stroke, and hypertension were identified as independent risk factors for PD, and dyslipidemia demonstrated an inverse result for PD.<\/jats:p>","DOI":"10.3390\/medicina57121292","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T05:42:10Z","timestamp":1638250930000},"page":"1292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Association between Gout and Parkinson\u2019s Disease: A Nationwide Population-Based Cohort Study in Korea"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-347X","authenticated-orcid":false,"given":"Ji Hyoun","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Ah","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea"},{"name":"Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju 28644, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-7799","authenticated-orcid":false,"given":"Aryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chungbuk National University Hospital, Cheongju 28644, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilwon","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Health Information and Management, College of Medicine, Chungbuk National University, Cheongju 28644, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrneurol.2015.249","article-title":"Parkinson\u2019s disease in 2015; evolving basic, pathological and clinical concepts in PD","volume":"12","author":"Kalia","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ene.12022","article-title":"EFNS\/MDS-ES\/ENS recommendations for the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Berardelli","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000110318","article-title":"Worldwide occurrence of Parkinson\u2019s disease: An updated review","volume":"12","author":"Zhang","year":"1993","journal-title":"Neuroepidemiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease; a systematic review and meta-analysis","volume":"29","author":"Preingsheim","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Han, S.L., Kim, S., Kim, H.T., Shin, H.W., Na, K.S., and Suh, H.S. (2019). Prevalence and incidence of Parkinson\u2019s disease and drug-induced parkinsonism in Korea. BMC Public Health, 19.","DOI":"10.1186\/s12889-019-7664-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","article-title":"Epidemiology of gout","volume":"40","author":"Roddy","year":"2014","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1365-2362.1997.1390687.x","article-title":"Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus","volume":"27","author":"Maxwell","year":"1997","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e003620","DOI":"10.1136\/bmjopen-2013-003620","article-title":"Low uric acid levels in patients with Parkinson\u2019s disease: Evidence from meta-analysis","volume":"3","author":"Shen","year":"2013","journal-title":"BMJ Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-014-7331-x","article-title":"Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: A meta-analysis","volume":"261","author":"Abraham","year":"2014","journal-title":"J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0404.1991.tb05013.x","article-title":"Oxidative stress as a cause of Parkinson\u2019s disease","volume":"136","author":"Jenner","year":"1991","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5607\/en.2013.22.1.11","article-title":"Role of oxidative stress in Parkinson\u2019s disease","volume":"22","author":"Hwang","year":"2013","journal-title":"Exp. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson\u2019s disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_15","unstructured":"National Health Insurance Service (NHIS) (2016, April 11). History of the NHIS. Available online: http:\/\/www.nhis.or.kr\/static\/html\/wbd\/g\/a\/wbdga0203.html."},{"key":"ref_16","first-page":"799","article-title":"Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Seong","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Singh, J.A., and Cleveland, J.D. (2019). Gout and the risk of Parkinson\u2019s disease in older adults: A study of U.S. Medicare data. BMC Neurol., 19.","DOI":"10.1186\/s12883-018-1234-x"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hu, L.Y., Yang, A.C., Lee, S.C., You, Z.H., Tsai, S.J., Hu, C.K., and Shen, C.C. (2020). Risk of Parkinson\u2019s disease following gout: A population-based retrospective cohort study in Taiwan. BMC Neurol., 20.","DOI":"10.1186\/s12883-020-01916-9"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbspin.2015.12.003","article-title":"Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: A primary care retrospective cohort study","volume":"84","author":"Janssens","year":"2017","journal-title":"Joint Bone Spine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ajh\/hpaa044","article-title":"Uric Acid and Hypertension: An Update with Recommendations","volume":"33","author":"Kelley","year":"2020","journal-title":"Am. J. Hypertens."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.107.129031","article-title":"Altered uric acid levels and disease states","volume":"324","author":"Kutzing","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Piani, F., Cicero, A.F.G., and Borghi, C. (2021). Uric Acid and Hypertension: Prognostic Role and Guide for Treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030448"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archneur.1983.04050030045008","article-title":"Epidemiology of Parkinson\u2019s disease in a Japanese city","volume":"40","author":"Harada","year":"1983","journal-title":"Arch. Neurol."},{"key":"ref_24","first-page":"8756359","article-title":"Variations in incidence and prevalence of Parkinson\u2019s disease in Taiwan: A population-based nationwide study","volume":"2016","author":"Liu","year":"2016","journal-title":"Parkinson\u2019s Dis."},{"key":"ref_25","first-page":"960","article-title":"Parkinson\u2019s disease in China","volume":"104","author":"Wang","year":"1991","journal-title":"Chin. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1212\/01.WNL.0000113727.73153.68","article-title":"Incidence of Parkinson disease and parkinsonism in three elderly populations of Central Spain","volume":"62","author":"Trincado","year":"2004","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ane.12694","article-title":"Parkinson\u2019s disease in Germany: Prevalence and incidence based on health claims data","volume":"136","author":"Nerius","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson\u2019s disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1468-1331.2012.03683.x","article-title":"Incidence and prevalence of Parkinson\u2019s disease in Buenos Aires City","volume":"19","author":"Bauso","year":"2012","journal-title":"Argent. Eur. J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","article-title":"Total cholesterol and the risk of Parkinson disease","volume":"70","author":"Hu","year":"2008","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3109\/00207454.2014.979288","article-title":"The serum lipid profile of Parkinson\u2019s disease patients: A study from China","volume":"125","author":"Guo","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/mds.27413","article-title":"Higher serum cholesterol and decreased Parkinson\u2019s disease risk: A statin-free cohort study","volume":"33","author":"Rozani","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/CIRCRESAHA.119.314929","article-title":"Lipids, apolipoproteins, and the risk of Parkinson disease","volume":"125","author":"Fang","year":"2019","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huang, X., Auinger, P., Eberly, S., Oakes, D., Schwarzschild, M., Ascherio, A., Mailman, R., Chen, H., and Parkinson Study Group DATATOP Investigators (2011). Serum Cholesterol and the Progression of Parkinson\u2019s Disease: Results from DATATOP. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022854"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12961297","DOI":"10.1126\/science.1066724","article-title":"Cholesterol\u2014Making or breaking the synapse","volume":"294","author":"Barres","year":"2001","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1038\/71366","article-title":"Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles","volume":"2","author":"Thiele","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_37","first-page":"669679","article-title":"Neurosteroid metabolism in the human brain","volume":"145","year":"2001","journal-title":"Eur. J. Endocrinol."},{"key":"ref_38","first-page":"169173","article-title":"The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens","volume":"16","author":"Mayo","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37573760","DOI":"10.1046\/j.1460-9568.1999.00816.x","article-title":"The neurosteroid pregnenolone sulphate increases dopamine release and the dopaminergic response to morphine in the rat nucleus accumbens","volume":"11","author":"Barrot","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000446655","article-title":"Statin use and its association with essential tremor and Parkinson\u2019s disease","volume":"47","author":"Shalaby","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbr.2016.04.046","article-title":"Statin use and risk of Parkinson\u2019s disease: A meta-analysis","volume":"309","author":"Seng","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104671","DOI":"10.1016\/j.nbd.2019.104671","article-title":"Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson\u2019s disease: What do prospective studies suggest","volume":"134","author":"Belvisi","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/bj2350747","article-title":"Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid","volume":"235","author":"Davies","year":"1986","journal-title":"Biochem. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/95.10.691","article-title":"Uric acid: An important antioxidant in acute ischemic stroke","volume":"95","author":"Waring","year":"2002","journal-title":"QJM"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acs.biomac.6b01547","article-title":"Iron chelation nanoparticles with delayed saturation as an effective therapy for Parkinson Disease","volume":"18","author":"Wang","year":"2017","journal-title":"Biomacromolecules"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J. Trace Elem. Med. Biol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:57Z","timestamp":1760168097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["medicina57121292"],"URL":"https:\/\/doi.org\/10.3390\/medicina57121292","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}